<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570918</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD014-01</org_study_id>
    <secondary_id>272201500032C-2-0-1</secondary_id>
    <nct_id>NCT03570918</nct_id>
  </id_info>
  <brief_title>MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label single-center study to determine the safety of MGD014 in&#xD;
      participants with human immunodeficiency virus (HIV) infection on stable suppressive&#xD;
      antiretroviral therapy (ART).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will be maintained on ART and receive either one infusion (Part 1) or&#xD;
      multiple infusions of MGD014 (Part 2). Part 1 is a single ascending dose study with a 1+3&#xD;
      design for the first 2 dose cohorts, and a 3+3 design with staggered accrual for the 6 higher&#xD;
      dose cohorts, with an aim of determining the safety, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of ascending doses up to either the Optimal Biologic Dose (OBD) or the&#xD;
      maximum administered dose (MAD).&#xD;
&#xD;
      Part 2 is a multi-dose expansion cohort with MGD014 administered at the OBD, as determined in&#xD;
      Part 1. In Part 2, additional assessments on the effects of MGD014 on HIV latent infection&#xD;
      parameters will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label dose-escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emerging Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>24 months</time_frame>
    <description>Area Under the Plasma Concentration versus Time Curve of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 months</time_frame>
    <description>Maximum Plasma Concentration of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 months</time_frame>
    <description>Time to maximal concentration of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>24 months</time_frame>
    <description>Trough plasma concentration of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>24 months</time_frame>
    <description>Total body clearance of the drug from plasma of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>24 months</time_frame>
    <description>Apparent volume of distribution at steady state of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>24 months</time_frame>
    <description>Terminal half life of MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>24 months</time_frame>
    <description>Percent of participants with anti-drug antibody to MGD014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment of serum cytokine levels following MGD014 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 infection markers</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of resting CD4 T-cell infection and levels of plasma HIV-1 RNA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>MGD014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-1 x CD3 bispecific DART molecule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGD014</intervention_name>
    <description>HIV-1 x CD3 bispecific DART molecule</description>
    <arm_group_label>MGD014</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability and willingness of participant to provide written informed consent.&#xD;
&#xD;
          -  HIV-1 infection, documented by any FDA-approved rapid HIV test or HIV enzyme or&#xD;
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and&#xD;
             confirmed by a licensed Western blot or a second antibody test by a method other than&#xD;
             the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.&#xD;
&#xD;
          -  On a potent, stable, continuous ART regimen for ≥ 24 months prior to Screening.&#xD;
&#xD;
          -  Plasma HIV-1 RNA &lt; 50 copies/mL at two time points in the previous 12 months prior to&#xD;
             screening (one time point can be screening) and never ≥ 50 copies/mL on 2 consecutive&#xD;
             time points in the last 24 months.&#xD;
&#xD;
          -  Adequate organ function based on acceptable laboratory parameters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential defined as any female who has experienced menarche and&#xD;
             who has not undergone successful surgical sterilization or menopause.&#xD;
&#xD;
          -  History or other evidence of severe illness, immunodeficiency other than HIV, or any&#xD;
             other condition that would make the potential participant unsuitable for study.&#xD;
&#xD;
          -  History or other evidence of any condition or process for which signs or symptoms&#xD;
             could be confused with reactions to MGD014.&#xD;
&#xD;
          -  History of any HIV immunotherapy or HIV vaccine except for MGD014 within 12 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  History of clinically significant cardiovascular disease, severe allergic reactions,&#xD;
             malignancy (except non-melanoma skin cancer) within 5 years, seizure disorder within 2&#xD;
             years, organ/tissue transplant, autoimmune disease, unstable asthma, bleeding&#xD;
             disorder.&#xD;
&#xD;
          -  Evidence of active viral, or antifungal treatment within 7 days prior to the&#xD;
             initiation of study drug&#xD;
&#xD;
          -  Active, asymptomatic, or suspected COVID-19/SARS-CoV-2 infection.&#xD;
&#xD;
          -  Active, untreated syphilis.&#xD;
&#xD;
          -  Use of blood products, cytokine therapy, growth-stimulating factors, cytotoxic&#xD;
             chemotherapy or investigational therapy within 90 days.&#xD;
&#xD;
          -  Current use of the antivirals maraviroc and/or enfuvirtide.&#xD;
&#xD;
          -  Any vaccination with exception of flu vaccine within 30 days of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chet Bohac, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, Latent HIV-1 infection, HIV therapy, antibody-based therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

